Abbreviated MRI vs. mpMRI for Prostate Cancer Detection
Abbreviated bpMRI as a Potential New Standard for Prostate Cancer Detection
Table of Contents
Could abbreviated biparametric magnetic resonance imaging (bpMRI) emerge as the new standard of care for prostate cancer (PCa) detection?
A recent multicenter study published in the Journal of the American Medical Association (JAMA) compared abbreviated bpMRI (T2-weighted and diffusion-weighted imaging (DWI)) with multiparametric MRI (mpMRI) in 490 biopsy-native men (median age 65, median PSA 5.6) with suspected PCa. The study involved 22 centers across 12 countries.
Key Findings
The study found comparable detection rates for clinically important PCa (csPCa) between the two methods:
- Abbreviated bpMRI: 29.2%
- mpMRI: 29.6%
Moreover, the following metrics were also similar:
| Metric | Abbreviated bpMRI | mpMRI |
|---|---|---|
| Sensitivity | 98% | 99.3% |
| Specificity | 61.6% | 60.1% |
| Positive Predictive Value (PPV) | 53.1% | 52.5% |
| Negative Predictive Value (NPV) | 98.6% | 99.5% |
Detection rates for clinically insignificant PCa were also comparable (9.2% vs. 9.6%).
Implications
According to lead author Alexander Ng,MBBS,the study demonstrates that abbreviated bpMRI can detect as much clinically significant cancer as mpMRI,without increasing the diagnosis of clinically insignificant cancer. Biopsy rates were also similar between the two methods.
Three Key Takeaways
- Comparable diagnostic accuracy. Abbreviated bpMRI performs similarly to mpMRI in detecting clinically significant prostate cancer.
- Reduced resource utilization. bpMRI is shorter and less resource-intensive then mpMRI.
- No increase in insignificant diagnoses. The study found no evidence that bpMRI leads to more diagnoses of clinically insignificant cancer.